CDK4 and breast carcinoma: Importantly, no effect on MCM3 expression was observed in ER+ breast cancer cell lines resistant to combined CDK4/6i and fulvestrant (MPF-R and TPF-R cells) after treatment with combined therapy (Fig. 6a).